Ambitious Study will help patients with inflammatory bowel disease

0
1016
Newcastle University
Newcastle University
0 0
Azadi Ka Amrit Mahoutsav

InterServer Web Hosting and VPS
Read Time:3 Minute, 53 Second

Ambitious Study will help patients with inflammatory bowel disease

Newcastle University finds out what causes the start and the severity of problems linked to inflammatory bowel disease, and patients, universities, hospitals, and pharmaceutical partners are collaborating.

June 27, 2024: An invaluable data resource comprising molecular, cellular, bacterial, viral, and genetic information will be made available by Open-IBD1, the largest study of its kind. The study, which will enrol 1,000 patients with irritable bowel disease (IBD), will gather comprehensive genomic and clinical data at diagnosis and at various points over a four-year period. Launched in advance of World IBD Day 2024, the £13 million project involves Newcastle University experts and is supported by Open Targets and the Wellcome Sanger Institute. The project’s ultimate goal is to find biomarkers to help enhance patient care and find novel, individualised approaches to predict, monitor, and treat conditions like ulcerative colitis and Crohn’s disease. These biomarkers might be used to track patients, determine which patients would benefit most from particular treatments, and discover possible targets for the creation of new medications. They might also offer light on the factors that contribute to and exacerbate IBD, explaining why some patients’ conditions worsen and advance more quickly than others.

“IBD can have a significant influence on a patient’s life, according to Dr. Chris Lamb, Open-IBD Clinical Lead at Newcastle University and Honorary Consultant in Gastroenterology at Newcastle Hospitals. The illness can be rather serious for a lot of people, and sadly, there are no effective treatments or those that do work only partially. We’re not sure why this is the case. Our mission with Open-IBD is to collaborate with patients to identify biomarkers that can inform individualised treatment plans, contribute to the understanding of why different people experience IBD in various ways, and offer new and customised solutions to those who experience this ailment. We feel that this ambitious project can truly benefit patients and the future of IBD therapy, especially as we are launching Open-IBD at a pivotal moment when the landscape of IBD treatment is shifting.”

All disorders causing persistent inflammation in the gastrointestinal tract are grouped together under the name IBD. There are two primary varieties: ulcerative colitis and Crohn’s disease. Patients who have experienced long-term symptoms of their illness and have tried a variety of treatments are the subjects of most IBD research. Understanding the underlying mechanisms causing IBD and the crucial pathways leading to the disease’s progression has become challenging due to these characteristics. Overcoming this issue, Open-IBD will enrol patients as soon as they are suspected of having IBD and before they receive any medication. Experts from academic institutions across the United Kingdom are brought together for Open-IBD, which will be led by co-Chief Investigators Dr. Carl Anderson from the Wellcome Sanger Institute and Dr. Chis Lamb from Newcastle University. Expert clinician scientists from specialised IBD clinics at seven hospitals will be recruited for the project. By early 2025, the researchers hope to have the first patients enrolled.

Researchers will take blood and stool samples from participants upon medical referral, in addition to comprehensive clinical data obtained through questionnaires. Furthermore, the biopsy samples obtained from patients undergoing diagnostic colonoscopies will be available to them. Additional samples will be obtained at regular intervals over the next two years, including one year after the diagnosis during a second colonoscopy. Single-cell RNA sequencing will be used for the analysis of biopsy and blood samples, while metagenomics shotgun sequencing and RNA gene sequencing will be applied to stool samples. All participants’ DNA samples will be sequenced in order to determine the genetic factors influencing the course and prognosis of the disease. Clinical data regarding the progression of the illness and the results of treatment will be gathered for a maximum of four years after consent is given.

ABOUT NEWCASTLE UNIVERSITY: Newcastle University, UK, is a thriving international community of more than 28,000 students from over 130 countries worldwide.As a member of the Russell Group of research-intensive universities in the UK, Newcastle has a world-class reputation for research excellence in the fields of medicine, science and engineering, social sciences and the humanities.Its academics are sharply focused on responding to the major challenges facing society today. Our research and teaching are world-leading in areas as diverse as health, culture, technology and the environment. Newcastle University is committed to providing our students with excellent, research-led teaching delivered by dedicated and passionate teachers. Newcastle University is ranked 110th  in the QS World Ranking 2024 and 139th in the Times Higher Education World University Ranking 2023.

About Post Author

Editor Desk

Antara Tripathy M.Sc., B.Ed. by qualification and bring 15 years of media reporting experience.. Coverred many illustarted events like, G20, ICC,MCCI,British High Commission, Bangladesh etc. She took over from the founder Editor of IBG NEWS Suman Munshi (15/Mar/2012- 09/Aug/2018 and October 2020 to 13 June 2023).
Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Advertisements

USD





LEAVE A REPLY

Please enter your comment!
Please enter your name here